Sivan Innovation

Company Overview

Snapshot

Founded in June 2014 by Daniel Israel, Sivan Innovation operates with 1–10 employees. The company is recognized for its digital therapy, Moovcare, which has demonstrated an increase of 7.6 months in overall survival for lung cancer patients and is reimbursed by health authorities in France.

Business overview

Sivan Innovation develops web applications for disease management, serving healthcare professionals and patients. Its core product, Moovcare, is a digital therapy designed for cancer patients that utilizes a smart algorithm to detect relapses and complications, sending immediate alerts to medical teams. Patients with lung cancer use the application to report symptoms via a weekly digital questionnaire, enabling oncologists to intervene as needed. The company operates within the Health Tech & Life Sciences sector, specifically in digital healthcare, patient remote monitoring, and digital therapeutics, leveraging artificial intelligence and mobile platforms.

Strategic signal

In August 2018, the Financial Times highlighted the potential of digital therapeutics, including solutions like Sivan Innovation's Moovcare, to disrupt healthcare. This recognition underscores the growing market validation for digital health interventions and signals a shift towards technology-driven patient management solutions, indicating a favorable environment for companies innovating in this space.

Company Intelligence Q&A

What is Sivan Innovation's primary product?

Sivan Innovation's primary product is Moovcare, a digital therapy designed for cancer patients that uses a smart algorithm to detect relapses and complications, sending immediate alerts to medical teams.

When was Sivan Innovation founded and by whom?

Sivan Innovation was founded in June 2014 by Daniel Israel.

In which countries does Sivan Innovation have offices?

Sivan Innovation has offices in Ra'anana, Israel, and Paris, France.

What impact has Moovcare demonstrated for lung cancer patients?

Moovcare has demonstrated an increase of 7.6 months in overall survival for lung cancer patients, along with a significant improvement in their quality of life.

Has Moovcare received reimbursement approval?

Moovcare is reimbursed by health authorities in France.